^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Medulloblastoma |
| Drug: | silmitasertib (CX-4945) (Casein kinase 2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Senhwa’s Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma
Published date:
08/17/2021
Excerpt:
Senhwa Biosciences, Inc....today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for Silmitasertib, a highly selective inhibitor of casein kinase 2 (CK2) to treat patients with recurrent sonic hedgehog (SHH) driven Medulloblastoma.
